Brazil sets a new chapter in its public health policy

July 12, 2019

During a seminar hosted by the Brazilian Association of the Pharmaceutical Research Industry (INTERFARMA) last week in Brasilia, the Minister of Health, Luiz Henrique Mandetta, said the country should never compulsory license drug patents, since this practice harms both the inventiveness and the investments made in R&D by private companies. This sets a new tone on the government’s position towards intellectual property for pharmaceutical products.

“There is no good in threatening to break patents. The country should never do this. We have to watch over the inventiveness and the time spent by researchers over the research counter. I know that each one of you spend hundreds of thousands of dollars to establish your compliance system [to comply with law and regulation], and that this is now mandatory inside the companies”, said Mandetta.

The Minister of Health’s speech is in line with the Ministry of Economy’s liberal positioning. The statement that “the country will not set a public health policy based on patent breaking” sets a new chapter in the Brazilian public health policy. The Minister addressed healthcare sector executives and stated that, since the private sector is the one responsible for providing drug production, the Government’s role should be to stimulate production initiatives.

During INTERFARMA’s seminar, the Minister of Health affirmed his commitment with innovation, as well as with providing public access to new pharmaceutical technologies through the Brazilian National Healthcare System (SUS). He also said the Government is currently revising the model it uses to incorporate healthcare therapies.

“The Ministry of Health has great expectations regarding the healthcare sector. The 21st century will be a wonderful century to live in. Each one of you can be in the imminence of announcing the next step, the next breakthrough. After deciphering the human genome and putting it at science and the pharmaceutical industry’s disposal, we knew we would have a century of innovations in genetics”, he said.

The seminar was attended by the Minister of Health, the Presidents of the House of Representatives and the Senate, Congressmen, the Brazilian Patent and Trademark Office’s (INPI) President, executives of the healthcare sector and other public officials. There were presented panels about intellectual property, the country’s economic landscape, innovation and clinical research.

Eduardo Hallak, partner at Licks Attorneys, also attended the event.

Public officials attend the Seminar “Healthcare Technological Innovations and its Value for Patients”. Photo: INTERFARMA.

RECENT POSTS

LINKEDIN FEED

Newsletter

Register your email and receive our updates

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

FOLLOW US ON SOCIAL MEDIA

Newsletter

Register your email and receive our updates-

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

FOLLOW US ON SOCIAL MEDIA

Licks Attorneys' Government Affairs & International Relations Blog

Doing Business in Brazil: Political and economic landscape

Licks Attorneys' COMPLIANCE Blog

Brazil sets a new chapter in its public health policy

During a seminar hosted by the Brazilian Association of the Pharmaceutical Research Industry (INTERFARMA) last week in Brasilia, the Minister of Health, Luiz Henrique Mandetta, said the country should never compulsory license drug patents, since this practice harms both the inventiveness and the investments made in R&D by private companies. This sets a new tone on the government’s position towards intellectual property for pharmaceutical products.

“There is no good in threatening to break patents. The country should never do this. We have to watch over the inventiveness and the time spent by researchers over the research counter. I know that each one of you spend hundreds of thousands of dollars to establish your compliance system [to comply with law and regulation], and that this is now mandatory inside the companies”, said Mandetta.

The Minister of Health’s speech is in line with the Ministry of Economy’s liberal positioning. The statement that “the country will not set a public health policy based on patent breaking” sets a new chapter in the Brazilian public health policy. The Minister addressed healthcare sector executives and stated that, since the private sector is the one responsible for providing drug production, the Government’s role should be to stimulate production initiatives.

During INTERFARMA’s seminar, the Minister of Health affirmed his commitment with innovation, as well as with providing public access to new pharmaceutical technologies through the Brazilian National Healthcare System (SUS). He also said the Government is currently revising the model it uses to incorporate healthcare therapies.

“The Ministry of Health has great expectations regarding the healthcare sector. The 21st century will be a wonderful century to live in. Each one of you can be in the imminence of announcing the next step, the next breakthrough. After deciphering the human genome and putting it at science and the pharmaceutical industry’s disposal, we knew we would have a century of innovations in genetics”, he said.

The seminar was attended by the Minister of Health, the Presidents of the House of Representatives and the Senate, Congressmen, the Brazilian Patent and Trademark Office’s (INPI) President, executives of the healthcare sector and other public officials. There were presented panels about intellectual property, the country’s economic landscape, innovation and clinical research.

Eduardo Hallak, partner at Licks Attorneys, also attended the event.

Public officials attend the Seminar “Healthcare Technological Innovations and its Value for Patients”. Photo: INTERFARMA.
Brazilian National Telecommunications Agency invites stakeholders to participate in event focused on the 5G technology
U.S. intensifies pressure on Brazilian Government to exclude Huawei from its 5G bid
Understand more about the subject of our webinar: Simplifying the Strategic Planning & Results Measurement in Government Affairs
BRICS sign MoU on Health Regulation
Mercosul and European Union close free trade deal
Brazil’s involvement in international organizations strengthened after votes by Senate
Brazilian Senate approves Regulatory Agencies’ Legal Framework
BRPTO takes on the pro tempore presidency of IP BRICS
INPIがIP BRICSの議長国に就任
ブラジル・イスラエルの二国間関係の復活
Brazil and Israel, the revival of the bilateral relationship
Jair Bolsonaro in Washington: Visit key points
Sergio Moro's Anti-Crime Package
Minister of Foreign Affairs travels to the US to prepare Bolsonaro’s visit next month
Bolsonaro and the future of Mercosul
Bolsonaro gives keynote address at the World Economic Forum
Prospects on Bolsonaro's foreign policy
The Brazilian Patent and Trademark Office (BRPTO) and the Japan Patent Office (JPO) renew Patent Prosecution Highway (PPH)
Federal Agencies will have until March to create anti-corruption programs
Brazil's Pension Reform